Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05272423 · ClinicalTrials.gov registry record
Studying Pathways of Resistance in KRAS-driven Cancers
A clinical trial of Kras P.G12C, sponsored by Addario Lung Cancer Medical Institute.
- Active
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT05272423 is a study of Kras P.G12C that is active but no longer recruiting, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05272423, a study of Kras P.G12C, is active but no longer recruiting, sponsored by Addario Lung Cancer Medical Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise in these settings.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST FoundationOne® Liquid CDx
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-09-08 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05272423
The ClinicalTrials.gov registry entry for NCT05272423 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Addario Lung Cancer Medical Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kras P.G12C appearing as the primary indexed condition, and to 1 intervention - of which FoundationOne® Liquid CDx is the first listed.
NCT05272423 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05272423 about?
NCT05272423 is a clinical study titled "Studying Pathways of Resistance in KRAS-driven Cancers". Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also c...
What is the current status of trial NCT05272423?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2022-09-08. Estimated completion is 2026-03.
What conditions does trial NCT05272423 study?
This clinical trial studies the following conditions: Kras P.G12C.
What interventions are being tested in trial NCT05272423?
The interventions under investigation include: FoundationOne® Liquid CDx (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05272423?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05272423 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kras P.G12C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.